U
Menu
M
Donate

Cardurion Clinical Drug Trial for the Treatment of CPVT 

CPVT: Cardurion Clinical Drug Trial for the Treatment of CPVT

Currently Enrolling
Phase 2
Sponsor: Cardurion Pharmaceuticals

Cardurion Pharma recently began enrolling participants for a clinical drug trial for the treatment of CPVT.

What are the basic eligibility criteria?

  • Over 18 years of age
  • Confirmed CPVT diagnosis, with a positive genetic test for RYR2. (If you have been diagnosed with CPVT but haven’t had genetic testing, SADS can help you with next steps. For resources on genetic testing click here to learn more, or email Genevie@SADS.org for help.)

FAQs

What is the drug being investigated, and how does it work?

This is a clinical study of CRD-4730 administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.

Where are the trial sites and how often would I need to travel there?

Listed below are the currently recruiting sites; when you sign up to participate, you will receive information to contact the site you’re interested in. More sites may open as the trial progresses.

Cincinnati, Ohio, USA
Houston ,Texas USA
Vancouver, British Columbia, Canada
Paris, France
Bron, France

The information contained herein is being made available as a public service by the SADS Foundation (SADS). No posted information or material provided is intended to constitute medical or professional advice. SADS makes no representations or warranties, either express or implied, as to the accuracy of any posted information and assumes no responsibility for any errors or omissions contained therein. SADS makes no representations or warranties, either express or implied, that any products or services adhere to or satisfy any standards or requirements that may be applicable to such product or service. Furthermore, no warranty, express or implied, is created by providing information and does not in any way constitute an endorsement by SADS. No one shall be entitled to claim detrimental reliance on any views or information, or to claim any duty on the part of SADS to update posted information. In no event shall SADS be held liable to you or anyone else for any decision made or action taken in reliance on such information or view.